FDA
-
-
-
-
-
-
-
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
-
-
-
-
-
-
-
Viking Therapeutics publishes Phase 2 obesity trial results in Obesity journal
-
-
-
-
-
-
-
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
-
-
-
-
-
-
-
Viking Therapeutics reports weight loss results from VK2735 oral trial
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Reports New Data from VK2735 Obesity Program
-
-
-
-
-
-
-
Ligand Reports First Quarter 2024 Financial Results
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

